|
1
|
Li K, Guo Q, Yang J, Chen H, Hu K, Zhao J,
Zheng S, Pang X, Zhou S, Dang Y, et al: FOXD3 is a tumor suppressor
of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway.
Oncotarget. 8:5048–5056. 2017.
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brosens LA, Offerhaus GJ and Giardiello
FM: Hereditary colorectal cancer: Genetics and screening. Surg Clin
North Am. 95:1067–1080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hahn MM, de Voer RM, Hoogerbrugge N,
Ligtenberg MJ, Kuiper RP and van Kessel AG: The genetic
heterogeneity of colorectal cancer predisposition - guidelines for
gene discovery. Cell Oncol (Dordr). 39:491–510. 2016. View Article : Google Scholar
|
|
6
|
Ruers T and Bleichrodt RP: Treatment of
liver metastases, an update on the possibilities and results. Eur J
Cancer. 38:1023–1033. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borner MM: Neoadjuvant chemotherapy for
unresectable liver metastases of colorectal cancer - too good to be
true? Ann Oncol. 10:623–626. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cai WS, Shen F, Feng Z, Chen JW, Liu QC,
Li EM, Xu B and Cao J: Downregulation of CDK-8 inhibits colon
cancer hepatic metastasis by regulating Wnt/β-catenin pathway.
Biomed Pharmacother. 74:153–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liao T, Qu N, Shi RL, Guo K, Ma B, Cao YM,
Xiang J, Lu ZW, Zhu YX, Li DS and Ji QH: BRAF-activated lncRNA
functions as a tumor suppressor in papillary thyroid cancer.
Oncotarget. 8:238–247. 2017.
|
|
10
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long noncoding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ayesh S, Matouk I, Schneider T, Ohana P,
Laster M, Al-Sharef W, De-Groot N and Hochberg A: Possible
physiological role of H19 RNA. Mol Carcinog. 35:63–74. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matouk IJ, DeGroot N, Mezan S, Ayesh S,
Abu-lail R, Hochberg A and Galun E: The H19 non-coding RNA is
essential for human tumor growth. PLoS One. 2:e8452007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Yu B, Li J, Su L, Yan M, Zhu Z and
Liu B: Overexpression of lncRNA H19 enhances carcinogenesis and
metastasis of gastric cancer. Oncotarget. 5:2318–2329. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hibi K, Nakamura H, Hirai A, Fujikake Y,
Kasai Y, Akiyama S, Ito K and Takagi H: Loss of H19 imprinting in
esophageal cancer. Cancer Res. 56:480–482. 1996.PubMed/NCBI
|
|
15
|
Cui H, Onyango P, Brandenburg S, Wu Y,
Hsieh CL and Feinberg AP: Loss of imprinting in colorectal cancer
linked to hypomethylation of H19 and IGF2. Cancer Res.
62:6442–6446. 2002.PubMed/NCBI
|
|
16
|
Lottin S, Adriaenssens E, Dupressoir T,
Berteaux N, Montpellier C, Coll J, Dugimont T and Curgy JJ:
Overexpression of an ectopic H19 gene enhances the tumorigenic
properties of breast cancer cells. Carcinogenesis. 23:1885–1895.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ariel I, Miao HQ, Ji XR, Schneider T, Roll
D, de Groot N, Hochberg A and Ayesh S: Imprinted H19 oncofetal RNA
is a candidate tumour marker for hepatocellular carcinoma. Mol
Pathol. 51:21–25. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Byun HM, Wong HL, Birnstein EA, Wolff EM,
Liang G and Yang AS: Examination of IGF2 and H19 loss of imprinting
in bladder cancer. Cancer Res. 67:10753–10758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai X and Cullen BR: The imprinted H19
noncoding RNA is a primary microRNA precursor. RNA. 13:313–316.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung
JJ and Kwok TT: Oncofetal H19-derived miR-675 regulates tumor
suppressor RB in human colorectal cancer. Carcinogenesis.
31:350–358. 2010. View Article : Google Scholar
|
|
21
|
Liu M, Wang D and Li N: MicroRNA-20b
downregulates HIF-1α and inhibits the proliferation and invasion of
osteosarcoma cells. Oncol Res. 23:257–266. 2016. View Article : Google Scholar
|
|
22
|
Robertson NM and Yigit MV: The role of
microRNA in resistance to breast cancer therapy. Wiley Interdiscip
Rev RNA. 5:823–833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamasaki T, Seki N, Yamada Y, Yoshino H,
Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Nakagawa M and
Enokida H: Tumor suppressive microRNA-138 contributes to cell
migration and invasion through its targeting of vimentin in renal
cell carcinoma. Int J Oncol. 41:805–817. 2012.PubMed/NCBI
|
|
24
|
Ye XW, Yu H, Jin YK, Jing XT, Xu M, Wan ZF
and Zhang XY: miR-138 inhibits proliferation by targeting
3-phosphoinositide-dependent protein kinase-1 in non-small cell
lung cancer cells. Clin Respir J. 9:27–33. 2015. View Article : Google Scholar
|
|
25
|
Chiappetta G, Manfioletti G, Pentimalli F,
Abe N, Di Bonito M, Vento MT, Giuliano A, Fedele M, Viglietto G,
Santoro M, et al: High mobility group HMGI(Y) protein expression in
human colorectal hyperplastic and neoplastic diseases. Int J
Cancer. 91:147–151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reeves R and Nissen MS: The
A.T-DNA-binding domain of mammalian high mobility group I
chromosomal proteins. A novel peptide motif for recognizing DNA
structure. J Biol Chem. 265:8573–8582. 1990.PubMed/NCBI
|
|
27
|
Shah SN, Cope L, Poh W, Belton A, Roy S,
Talbot CC Jr, Sukumar S, Huso DL and Resar LM: HMGA1: A master
regulator of tumor progression in triple-negative breast cancer
cells. PLoS One. 8:e634192013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Belton A, Gabrovsky A, Bae YK, Reeves R,
Iacobuzio-Donahue C, Huso DL and Resar LM: HMGA1 induces intestinal
polyposis in transgenic mice and drives tumor progression and stem
cell properties in colon cancer cells. PLoS One. 7:e300342012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chiappetta G, Botti G, Monaco M,
Pasquinelli R, Pentimalli F, Di Bonito M, D'Aiuto G, Fedele M,
Iuliano R, Palmieri EA, et al: HMGA1 protein overexpression in
human breast carcinomas: correlation with ErbB2 expression. Clin
Cancer Res. 10:7637–7644. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matouk IJ, Raveh E, Abu-lail R, Mezan S,
Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M,
et al: Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys
Acta. 1843:1414–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lustig-Yariv O, Schulze E, Komitowski D,
Erdmann V, Schneider T, de Groot N and Hochberg A: The expression
of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines.
Is H19 a tumor suppressor gene? Oncogene. 15:169–177. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsang WP and Kwok TT: Riboregulator H19
induction of MDR1-associated drug resistance in human
hepatocellular carcinoma cells. Oncogene. 26:4877–4881. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li S, Yu Z, Chen SS, Li F, Lei CY, Chen
XX, Bao JM, Luo Y, Lin GZ, Pang SY, et al: The YAP1 oncogene
contributes to bladder cancer cell proliferation and migration by
regulating the H19 long noncoding RNA. Urol Oncol.
33:427.e1–427.e10. 2015. View Article : Google Scholar
|
|
34
|
Han D, Gao X, Wang M, Qiao Y, Xu Y, Yang
J, Dong N, He J, Sun Q, Lv G, et al: Long noncoding RNA H19
indicates a poor prognosis of colorectal cancer and promotes tumor
growth by recruiting and binding to eIF4A3. Oncotarget.
7:22159–22173. 2016.PubMed/NCBI
|
|
35
|
Dhar A, Hu J, Reeves R, Resar LM and
Colburn NH: Dominant-negative c-Jun (TAM67) target genes: HMGA1 is
required for tumor promoter-induced transformation. Oncogene.
23:4466–4476. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kong H, Wu Y, Zhu M, Zhai C, Qian J, Gao
X, Wang S, Hou Y, Lu S and Zhu H: Long non-coding RNAs: Novel
prognostic biomarkers for liver metastases in patients with early
stage colorectal cancer. Oncotarget. 7:50428–50436. 2016.PubMed/NCBI
|
|
37
|
Wei JJ, Wu X, Peng Y, Shi G, Basturk O,
Yang X, Daniels G, Osman I, Ouyang J, Hernando E, et al: Regulation
of HMGA1 expression by microRNA-296 affects prostate cancer growth
and invasion. Clin Cancer Res. 17:1297–1305. 2011. View Article : Google Scholar :
|
